Teva Can't Dodge GSK's Wellbutrin False Ad Suit

Law360, New York (March 10, 2014, 8:45 PM EDT) -- A Pennsylvania federal judge refused Monday to dismiss GlaxoSmithKline LLC's lawsuit accusing Teva Pharmaceuticals USA Inc. of falsely advertising a generic antidepressant as equivalent to GSK's brand-name version, saying it was not preempted by a past U.S. Food and Drug Administration finding.

GSK is accusing Teva of damaging its reputation and endangering consumer health by promoting the generic Budeprion XL as having the same therapeutic effect as GSK's Wellbutrin XL, when in reality, it entered the bloodstream at a much faster rate than the GSK drug...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC.


Case Number

2:13-cv-00726

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Other Statutory Actions

Judge

EDUARDO C. ROBRENO

Date Filed

February 7, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.